Medicare Benefits Schedule - Item 73295

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with advanced (FIGO III-IV) high-grade serous or high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible, requested by a specialist or consultant physician, to determine eligibility for treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS) 

Maximum of one test per patient’s lifetime

Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,106.80

(See para PN.0.27 of explanatory notes to this Category)

• Previous - Item 73294
• Next - Item 73296

Items 73295, 73296, 73304, 73333, 73392, 73395, 73416 and 73419.

Patients who are found to have any form of affected allele should be referred for post-test genetic counselling as there may be implications for other family members. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral.

Items 73416 and 73392

The rapidly expanding field of genomic medicine has resulted in recognition of an increasing number of genetic causes of
cardiac diseases. Use of genomic testing methods that permit reanalysis of existing data for variants in newly described
clinically relevant genes are recommended/encouraged.

Related Items: 73295 73296 73304 73333 73392 73395 73416 73419